CTE Clinical Trials 2024

CTE Clinical Trials 2024

CTE research studies recruiting patients in 2024 need your help. Receive premium care & cutting edge treatments by enrolling in chronic traumatic encephalopathy clinical trials today.

CTE Clinical Trials

Here are the 6 most popular medical studies for cte

Toronto, Ontario

Macrolide Antibiotic

Azithromycin for Cystic Fibrosis

Recruiting2 awardsPhase 2
Toronto, Ontario

Pulmonary infection with Burkholderia cepacia complex (BCC) in patients with CF is often associated with a more rapid decline in lung function. Because of the resistance of BCC to many antibiotics, treatment options are often limited. New therapies to improve outcomes for patients infected with BCC are needed. However, because of the unpredictable nature of this pulmonary infection in CF, patients with BCC infection have been excluded from many CF therapeutic trials. Recent published trials in the United States, Australia, and the United Kingdom have all demonstrated clinical benefits from prolonged administration of azithromycin in CF. In these trials, the vast majority of patients were chronically infected with Pseudomonas aeruginosa. Patients with BCC were excluded from the US and UK trials, and only four patients with BCC infection were enrolled in the Australian trial. Thus, the effectiveness of azithromycin in CF patients infected with BCC is largely unknown and deserves further study. The two main ways by which azithromycin is thought to help with the chronic lung infections seen in CF are by [a] reducing inflammation and [b] direct effects on the bacteria, in particular P. aeruginosa. BCC pulmonary infection in CF is often associated with a large inflammatory response similar to or more severe than P. aeruginosa infection. If azithromycin works mainly by an anti-inflammatory mechanism, it should also be helpful in CF patients infected with BCC. Alternatively, azithromycin could have a direct effect on BCC as seen with P. aeruginosa as the two bacteria have many similarities.

Popular filter options for cte trials

HIV Clinical Trials

View 10 HIV medical studies.

Neuropathy Clinical Trials

View 9 Neuropathy medical studies.

Phase 3 Cte Clinical Trials

View 70 phase 3 cte medical studies.

Cte Clinical Trials With No Placebo

View 70 cte medical studies that do not have a placebo group.

Frequently Asked Questions

Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the 'trial drug' — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
Is there any support for travel costs?
Many of the teams running clinical trials will cover the cost of transportation to-and-from their care center.
Will I know what medication I am taking?
This depends on the specific study. If you're worried about receiving a placebo, you can actively filter out these trials using our search.
How long do clinical trials last?
Some trials will only require a single visit, while others will continue until your disease returns. It's fairly common for a trial to last somewhere between 1 and 6 months.
Do you verify all the trials on your website?
All of the trials listed on Power have been formally registered with the US Food and Drug Administration. Beyond this, some trials on Power have been formally 'verified' if the team behind the trial has completed an additional level of verification with our team.
How quickly will I hear back from a clinical trial?
Sadly, this response time can take anywhere from 6 hours to 2 weeks. We're working hard to speed up how quickly you hear back — in general, verified trials respond to patients within a few days.

Introduction to cte

What are the top hospitals conducting cte research?

Chronic Traumatic Encephalopathy (CTE) is a complex neurodegenerative condition that has gained significant attention in recent years due to its association with repeated head injuries, particularly in contact sports. In the quest for understanding and finding effective treatments for CTE, top hospitals are leading the way in conducting clinical trials. Among these institutions is the esteemed Dana-Farber Cancer Institute based in Boston. With five ongoing CTE trials, they are at the forefront of research into this debilitating condition. Similarly, Memorial Sloan Kettering Cancer Center in New york also prioritizes CTE research with an equal number of active trials aimed at unraveling the complexities surrounding this disorder.

Adding to these efforts is Tufts Medical Center, another renowned hospital located in Boston, where four active clinical trials focusing on CTE are currently underway. Not limited to just one region, two other notable locations involved in combating CTE through clinical research include a Research Site based out of New York and another situated in Montreal—each contributing three ongoing clinical trials dedicated to uncovering new insights about this challenging condition.

It's important to note that while these hospitals have made significant contributions by initiating several active studies related to CTE treatment and understanding; there hasn't been any recorded completed trial as yet highlighting how crucial it remains for further exploration into potential interventions or preventive measures against this progressive neurological disorder affecting individuals exposed to repetitive brain trauma.

The dedication shown by these institutions reflects their commitment not only toward alleviating the suffering caused by CTE but also fostering scientific progress that could reshape our approach towards preventing long-term consequences associated with traumatic brain injuries. By driving forward innovative research initiatives focused on improving our knowledge surrounding chronic traumatic encephalopathy, they offer hope for future generations impacted by head trauma and inspire collective efforts aimed at safeguarding athletes' well-being worldwide

Which are the best cities for cte clinical trials?

When it comes to clinical trials for chronic traumatic encephalopathy (CTE), several cities emerge as top contenders in research and development. New york, with 30 active trials, focuses on investigating treatments like Pembrolizumab and SRS, PF-07062119, among others. Los Angeles follows closely behind with 19 ongoing studies exploring interventions such as Durvalumab, Abemaciclib, and patients diagnosed with pulmonary arterial hypertension (PAH) or CTEPH. Atlanta boasts 17 active trials examining options like palliative radiation therapy, Maraviroc, ALIS, and more. Lastly, Chicago offers 16 active trials that delve into treatments including oral Cabotegravir (CAB), Durvalumab, Trastuzumab deruxtecan. Together these cities provide access to cutting-edge clinical trials for individuals battling CTE across the United States.

Which are the top treatments for cte being explored in clinical trials?

Clinical trials are actively exploring several promising treatments for Chronic Traumatic Encephalopathy (CTE). The top contenders in these trials include:

  • Treatment A: Currently being tested in X number of active CTE trials and Y number of all-time clinical trials.
  • Treatment B: Under investigation in Z number of ongoing CTE studies and W number of all-time clinical trials.
  • Treatment C: Showing potential with Q number of active CTE trials and R number of all-time clinical trials.

These innovative treatments offer hope for those affected by this debilitating condition, as researchers continue their relentless pursuit to find effective therapies for CTE.

What are the most recent clinical trials for cte?

Promising developments in clinical trials offer hope for those affected by chronic traumatic encephalopathy (CTE). One significant trial involves ASKG915, a potential treatment currently undergoing Phase 1 testing. Additionally, LB2102 is an experimental therapy showing promise in its Phase 1 trial for CTE patients. Immunotherapy has also emerged as a potential avenue, with the combination of avelumab and lurbinectedin being evaluated during Phase 2 trials. The TAK-861 Dose 1 trial has advanced to both Phase 2 and Phase 3 stages, offering further possibilities for effective CTE treatments. These recent clinical trials provide optimism that innovative therapies will soon be available to improve the lives of individuals living with CTE.

What cte clinical trials were recently completed?

Recently completed clinical trials for chronic traumatic encephalopathy (CTE) are paving the way for enhanced understanding and potential treatments of this debilitating condition. Notably, a trial sponsored by Washington University School of Medicine was concluded in October 2021, focusing on addressing key aspects of CTE. The dedication to research is evident as scientists strive to unlock new insights into the complexities of CTE and develop strategies that could bring hope to individuals affected by this neurodegenerative disease.